Crispr Therapeutics AG (CRSP) Annual Income Statement (USD)
CRSP Quarterly Financials (USD)
Frequently Asked Questions About Crispr Therapeutics AG (CRSP) Stock
Crispr Therapeutics AG's (CRSP) last reported annual revenue was USD 371.21 Million.
Crispr Therapeutics AG's (CRSP) annual revenue growth rate based on the revenue reported in the past 5 years is : 160.00%
Crispr Therapeutics AG's(CRSP) is not profitable as of its last reported annual financials.
The net profit margin for Crispr Therapeutics AG's(CRSP) from its laster reported year is -41.38%
The return on equity (ROE) for Crispr Therapeutics AG's(CRSP) from its last reported annual financials is : -13.07%
The return on assets (ROA) for Crispr Therapeutics AG's(CRSP) from its last reported annual financials is : -9.57%
The return on invested capital (ROIC) for Crispr Therapeutics AG's(CRSP) from its last reported annual financials is : -12.00%
The Debt to Equity ratio for Crispr Therapeutics AG's(CRSP) from its last reported annual financials is : 0.00%
The dividend yield for Crispr Therapeutics AG's(CRSP) from its laster reported year is 0.00%
Crispr Therapeutics AG's(CRSP) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRSP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
